ResearcherDalian Medical UniversityActive in the last 2 years
Zeyao Tang
Matched on ORCID iD 0000-0003-2412-5871; OpenAlex author ID A5090837482. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 8
2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper
Papers 5
- Corrigendum "Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabine resistant pancreatic cancer cells" [P… Co-author DOI 10.1016/j.phymed.2024.156301↗
- Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabine resistant pancreatic cancer cells. Co-author DOI 10.1016/j.phymed.2021.153711↗
- miR-421 up-regulation by the oleanolic acid derivative K73-03 regulates epigenetically SPINK1 transcription in pancreatic cancer cells leading to metabolic cha… Co-author DOI 10.1016/j.phrs.2020.105130↗
- Selaginellin B induces apoptosis and autophagy in pancreatic cancer cells via the JAK2/STAT3 signaling pathway. Co-author PMID 33312355↗
- Anticancer effect of SZC015 on pancreatic cancer via mitochondria-dependent apoptosis and the constitutive suppression of activated nuclear factor κB and STAT3… Last author DOI 10.1002/jcp.26892↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Peng Chu · 5 shared papers, 2018–2025 · strength 0.59
- Paper Corrigendum "Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabi… DOI 10.1016/j.phymed.2024.156301↗
- Paper Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabine resistant … DOI 10.1016/j.phymed.2021.153711↗
- Paper Selaginellin B induces apoptosis and autophagy in pancreatic cancer cells via the JAK2/STAT3 signaling pathway. PMID 33312355↗
- Abdullah Shopit · 4 shared papers, 2020–2025 · strength 0.51
- Paper Corrigendum "Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabi… DOI 10.1016/j.phymed.2024.156301↗
- Paper Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabine resistant … DOI 10.1016/j.phymed.2021.153711↗
- Paper Selaginellin B induces apoptosis and autophagy in pancreatic cancer cells via the JAK2/STAT3 signaling pathway. PMID 33312355↗
- Jinyong Peng · 4 shared papers, 2018–2025 · strength 0.50
- Paper Corrigendum "Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabi… DOI 10.1016/j.phymed.2024.156301↗
- Paper Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabine resistant … DOI 10.1016/j.phymed.2021.153711↗
- Paper Selaginellin B induces apoptosis and autophagy in pancreatic cancer cells via the JAK2/STAT3 signaling pathway. PMID 33312355↗
- Xiaodong Ma · 3 shared papers, 2020–2025 · strength 0.43
- Paper Corrigendum "Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabi… DOI 10.1016/j.phymed.2024.156301↗
- Paper Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabine resistant … DOI 10.1016/j.phymed.2021.153711↗
- Paper Selaginellin B induces apoptosis and autophagy in pancreatic cancer cells via the JAK2/STAT3 signaling pathway. PMID 33312355↗
- Xiaohong H. Shu · 2 shared papers, 2021–2025 · strength 0.32
- Paper Corrigendum "Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabi… DOI 10.1016/j.phymed.2024.156301↗
- Paper Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabine resistant … DOI 10.1016/j.phymed.2021.153711↗
- Zhaolin Sun · 1 shared paper, 2020 · strength 0.10
- Yanlin Song · 1 shared paper, 2018 · strength 0.07
- Bin Sun · 1 shared paper, 2018 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.